Epithelial ovarian cancer (OC) is one of the leading causes of cancer-related deaths amongst women worldwide despite gains in diagnostic approaches and treatment over the last three decades. Existing biomarkers of OC progression possess very limited clinical reliability, highlighting the emerging need for identification of novel prognostic biomarkers that allow the stratification of patients who could benefit from different therapeutic approaches. In this chapter, we summarize the genomic analysis in OC. Large-scale high-throughput genomic technologies have been used to characterize this cancer and identify dysregulated genes and aberrantly activated signaling pathways. Such technologies can complement well-established clinical histopathology analysis to result in better, more tailored treatments in the future. Genomic signatures obtained by gene expression profiling of OC may be able to predict survival outcomes, chemo response, the success of surgical treatment and allow for the identification of novel predictive biomarkers for purposes of treatment planning. These data combined suggest a pathway to improve the treatment of advanced OC and the promise to provide personalized medicine to women with OC.
Ceppi, L., Birrer, M. (2017). Ovarian Cancer Genomics. In Translational Advances in Gynecologic Cancers (pp. 19-34). Elsevier Inc. [10.1016/B978-0-12-803741-6.00002-1].
Ovarian Cancer Genomics
Ceppi L.Primo
;
2017
Abstract
Epithelial ovarian cancer (OC) is one of the leading causes of cancer-related deaths amongst women worldwide despite gains in diagnostic approaches and treatment over the last three decades. Existing biomarkers of OC progression possess very limited clinical reliability, highlighting the emerging need for identification of novel prognostic biomarkers that allow the stratification of patients who could benefit from different therapeutic approaches. In this chapter, we summarize the genomic analysis in OC. Large-scale high-throughput genomic technologies have been used to characterize this cancer and identify dysregulated genes and aberrantly activated signaling pathways. Such technologies can complement well-established clinical histopathology analysis to result in better, more tailored treatments in the future. Genomic signatures obtained by gene expression profiling of OC may be able to predict survival outcomes, chemo response, the success of surgical treatment and allow for the identification of novel predictive biomarkers for purposes of treatment planning. These data combined suggest a pathway to improve the treatment of advanced OC and the promise to provide personalized medicine to women with OC.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
